
Bio Essence Corp
97
Recent developments include Bio Essence's announcement of a Regulation A Tier 2 offering for up to $5 million in early 2026. The company continues to operate with a focus on herbal supplements and OEM services amid ongoing legal proceedings.
- Bio Essence Corp announced the commencement of a Regulation A Tier 2 offering for up to $5.0 million in February 2026 [N1].
Bio Essence Corp is a California-based herbal health, diet, and nutrition company incorporated in 2000. It provides herbal health, diet, and vitamin nutritional supplements primarily through OEM services. The company historically operated through subsidiaries focused on manufacturing and traditional Chinese medicines but has since sold or dissolved these entities and now manages operations directly while outsourcing manufacturing. The company has a small workforce and is headquartered in Irvine, California.
Bio Essence Corp is an herbal health and nutrition company focused on herbal supplements and OEM services. The company operates primarily through direct management and outsourcing after divesting its manufacturing subsidiaries. As of September 30, 2026, Bio Essence reported $4.0 million in total assets, $1.7 million in liabilities, and positive stockholders' equity of $2.29 million. Revenues for the third quarter of 2026 were $253,020 with a net loss of $150,458. The company faces a legal dispute alleging breach of contract and lease obligations with claims of approximately $1.5 million, which it denies. Bio Essence announced a Regulation A Tier 2 offering for up to $5 million in early 2026. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Bio Essence's restructuring to operate directly and outsource manufacturing could reduce fixed costs and increase operational flexibility. The company's intangible assets and OEM service revenues provide a foundation for growth in the herbal supplement market. The recent Regulation A Tier 2 offering may provide capital to support business initiatives and expansion.
The company faces significant legal risks from a lawsuit alleging breach of contract and lease obligations with claims exceeding $1.5 million. Liquidity ratios indicate limited short-term financial flexibility, with a current ratio of 0.17 and cash ratio of 0.02 as of September 30, 2026. Continued net losses and reliance on outsourced manufacturing may constrain profitability and operational control.
Bio Essence's moat is centered on its niche focus in herbal health and traditional Chinese medicine supplements, leveraging OEM manufacturing relationships. However, the divestiture of its manufacturing subsidiaries and reliance on outsourcing may limit proprietary manufacturing advantages. The company's intangible assets and established customer relationships contribute to its competitive position in the herbal supplement market.
• Legal Proceedings: Bio Essence is involved in litigation alleging breach of contract and lease obligations related to a commercial property, with claims totaling approximately $1.5 million. The outcome of this case could materially affect the company's financial position.
• Liquidity Constraints: The company's liquidity ratios as of September 30, 2026 indicate limited short-term financial flexibility, with a current ratio of 0.17 and cash ratio of 0.02, which may impact its ability to meet obligations.
• Operational Dependence on Outsourcing: Following the sale and dissolution of its manufacturing subsidiaries, Bio Essence relies on outsourced manufacturing and OEM services, which may affect control over production quality and costs.
Business trends: Transition to direct management and outsourcing of manufacturing post-divestiture; focus on herbal supplements and OEM services.
Execution milestones: Completion of Regulation A Tier 2 offering; resolution of ongoing legal dispute.
Key risks: Legal proceedings alleging breach of contract and lease obligations; limited liquidity; dependence on outsourced manufacturing.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Bio Essence Corp is an herbal health, diet, and nutrition company focused on providing herbal health, diet, and vitamin nutritional supplements.
- The company was incorporated in California on January 1, 2000, and underwent a change of control in 2016.
- Bio Essence operates as a holding company with subsidiaries historically including Bio Essence Pharmaceutical, Inc. (BEP), Bio Essence Herbal Essentials Inc. (BEH), and McBE Pharma, Inc., though BEP and BEH were sold in 2023 and 2024 respectively, and McBE was dissolved in 2024.
- Post-sale of subsidiaries, Bio Essence manages operations directly and outsources manufacturing and OEM services.
- The company is headquartered in Irvine, California, with 4 full-time employees as of the latest filings.
- As of September 30, 2026, Bio Essence reported total assets of approximately $4.0 million, including $278,919 in current assets and $3.7 million in non-current assets primarily intangible assets.
- Current liabilities as of September 30, 2026 were approximately $1.65 million, with total liabilities around $1.7 million.
- Stockholders' equity was positive at approximately $2.29 million as of September 30, 2026, reflecting an improvement from a deficit position at the end of 2025.
- The company reported revenues of $253,020 for the three months ended September 30, 2026, primarily from OEM services.
- Net income for the same period was a loss of $150,458.
- Liquidity ratios as of September 30, 2026 indicate a current ratio of 0.17 and a cash ratio of 0.02, reflecting limited short-term liquidity.
- The company is involved in a legal proceeding alleging breach of contract and lease obligations related to a commercial space, with claims totaling approximately $1.5 million; Bio Essence denies the allegations and plans counterclaims.
- Bio Essence announced a Regulation A Tier 2 offering for up to $5.0 million in February 2026.
- The company has issued and outstanding common stock shares of approximately 55.8 million as of September 30, 2026.
- Recent news coverage includes a press release about the Regulation A offering and general market news unrelated directly to Bio Essence.
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Generated 2026-11-15
- S1 | 2026-03-27 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-15 | www.nasdaq.com | Nvidia's Ousted CEO Said a 1-Gigawatt Data Center Delay Costs $10 Billion a Quarter. Here's Why That Matters for Power Stocks. | https://www.nasdaq.com/articles/nvidias-ousted-ceo-said-1-gigawatt-data-center-delay-costs-10-billion-quarter-heres-why
- N2 | 2026-11-15 | www.nasdaq.com | Ralph Lauren: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/ralph-lauren-3-key-takeaways-long-term-investors
- N3 | 2026-11-15 | www.nasdaq.com | Regis: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/regis-3-key-takeaways-long-term-investors
- N4 | 2026-11-15 | www.nasdaq.com | Cars.com: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/carscom-3-key-takeaways-long-term-investors
- N5 | 2026-11-15 | www.nasdaq.com | Canada Goose: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/canada-goose-3-key-takeaways-long-term-investors
- N6 | 2026-11-14 | www.nasdaq.com | Elon Musk's Tesla and SpaceX Lost More Than $420 Billion in Combined Market Value in Two Days After Democrats Swept the Midterms, With Investors Fearing New Congressional Probes. Here's Why That Political Risk Matters for Shareholders | https://www.nasdaq.com/articles/elon-musks-tesla-and-spacex-lost-more-420-billion-combined-market-value-two-days-after
- N7 | 2026-08-15 | www.nasdaq.com | Dollar Falls on Weak US Retail Sales and Consumer Sentiment Reports | https://www.nasdaq.com/articles/dollar-falls-weak-us-retail-sales-and-consumer-sentiment-reports-0
- N8 | 2026-08-15 | www.nasdaq.com | Which Is the Better Dividend ETF: Schwab's Defensive SCHD or Fidelity's Tech-Tilted FDVV? | https://www.nasdaq.com/articles/which-better-dividend-etf-schwabs-defensive-schd-or-fidelitys-tech-tilted-fdvv
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


